Polo-like Kinase 2, a Novel ADAM17 Signaling Component, Regulates Tumor Necrosis Factor similar to Ectodomain Shedding

Schwarz J, Schmidt S, Will O, Koudelka T, Koehler K, Boss M, Rabe B, Tholey A, Scheller J, Schmidt-Arras D, Schwake M, et al. (2014)
Journal of Biological Chemistry 289(5): 3080-3093.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ; ; ; ; ; ;
All
Abstract
Background: The metalloprotease ADAM17 emerged as the main sheddase of several cytokines and cytokine receptors. Results: The acidophilic kinase PLK2 interacts with and phosphorylates ADAM17 in mammalian cells. Conclusion: PLK2 represents a novel cellular interaction partner of ADAM17 modulating its activity. Significance: Regulation of ADAM17 activity is essential for inflammatory responses. ADAM17 (a disintegrin and metalloprotease 17) controls pro- and anti-inflammatory signaling events by promoting ectodomain shedding of cytokine precursors and cytokine receptors. Despite the well documented substrate repertoire of ADAM17, little is known about regulatory mechanisms, leading to substrate recognition and catalytic activation. Here we report a direct interaction of the acidophilic kinase Polo-like kinase 2 (PLK2, also known as SNK) with the cytoplasmic portion of ADAM17 through the C-terminal noncatalytic region of PLK2 containing the Polo box domains. PLK2 activity leads to ADAM17 phosphorylation at serine 794, which represents a novel phosphorylation site. Activation of ADAM17 by PLK2 results in the release of pro-TNF and TNF receptors from the cell surface, and pharmacological inhibition of PLK2 leads to down-regulation of LPS-induced ADAM17-mediated shedding on primary macrophages and dendritic cells. Importantly, PLK2 expression is up-regulated during inflammatory conditions increasing ADAM17-mediated proteolytic events. Our findings suggest a new role for PLK2 in the regulation of inflammatory diseases by modulating ADAM17 activity.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Schwarz J, Schmidt S, Will O, et al. Polo-like Kinase 2, a Novel ADAM17 Signaling Component, Regulates Tumor Necrosis Factor similar to Ectodomain Shedding. Journal of Biological Chemistry. 2014;289(5):3080-3093.
Schwarz, J., Schmidt, S., Will, O., Koudelka, T., Koehler, K., Boss, M., Rabe, B., et al. (2014). Polo-like Kinase 2, a Novel ADAM17 Signaling Component, Regulates Tumor Necrosis Factor similar to Ectodomain Shedding. Journal of Biological Chemistry, 289(5), 3080-3093.
Schwarz, J., Schmidt, S., Will, O., Koudelka, T., Koehler, K., Boss, M., Rabe, B., Tholey, A., Scheller, J., Schmidt-Arras, D., et al. (2014). Polo-like Kinase 2, a Novel ADAM17 Signaling Component, Regulates Tumor Necrosis Factor similar to Ectodomain Shedding. Journal of Biological Chemistry 289, 3080-3093.
Schwarz, J., et al., 2014. Polo-like Kinase 2, a Novel ADAM17 Signaling Component, Regulates Tumor Necrosis Factor similar to Ectodomain Shedding. Journal of Biological Chemistry, 289(5), p 3080-3093.
J. Schwarz, et al., “Polo-like Kinase 2, a Novel ADAM17 Signaling Component, Regulates Tumor Necrosis Factor similar to Ectodomain Shedding”, Journal of Biological Chemistry, vol. 289, 2014, pp. 3080-3093.
Schwarz, J., Schmidt, S., Will, O., Koudelka, T., Koehler, K., Boss, M., Rabe, B., Tholey, A., Scheller, J., Schmidt-Arras, D., Schwake, M., Rose-John, S., Chalaris, A.: Polo-like Kinase 2, a Novel ADAM17 Signaling Component, Regulates Tumor Necrosis Factor similar to Ectodomain Shedding. Journal of Biological Chemistry. 289, 3080-3093 (2014).
Schwarz, Jeanette, Schmidt, Stefanie, Will, Olga, Koudelka, Tomas, Koehler, Kaja, Boss, Melanie, Rabe, Bjoern, Tholey, Andreas, Scheller, Juergen, Schmidt-Arras, Dirk, Schwake, Michael, Rose-John, Stefan, and Chalaris, Athena. “Polo-like Kinase 2, a Novel ADAM17 Signaling Component, Regulates Tumor Necrosis Factor similar to Ectodomain Shedding”. Journal of Biological Chemistry 289.5 (2014): 3080-3093.
This data publication is cited in the following publications:
This publication cites the following data publications:

6 Citations in Europe PMC

Data provided by Europe PubMed Central.

Structural analysis of the polo-box domain of human Polo-like kinase 2.
Kim JH, Ku B, Lee KS, Kim SJ., Proteins 83(7), 2015
PMID: 25846005
Identification of multiple DNA copy number alterations including frequent 8p11.22 amplification in conjunctival squamous cell carcinoma.
Asnaghi L, Alkatan H, Mahale A, Othman M, Alwadani S, Al-Hussain H, Jastaneiah S, Yu W, Maktabi A, Edward DP, Eberhart CG., Invest. Ophthalmol. Vis. Sci. 55(12), 2014
PMID: 25491297
Identification of the PLK2-dependent phosphopeptidome by quantitative proteomics [corrected].
Franchin C, Cesaro L, Pinna LA, Arrigoni G, Salvi M., PLoS ONE 9(10), 2014
PMID: 25338102
GSK3 and Polo-like kinase regulate ADAM13 function during cranial neural crest cell migration.
Abbruzzese G, Cousin H, Salicioni AM, Alfandari D., Mol. Biol. Cell 25(25), 2014
PMID: 25298404
Amyloid precursor protein regulates migration and metalloproteinase gene expression in prostate cancer cells.
Miyazaki T, Ikeda K, Horie-Inoue K, Inoue S., Biochem. Biophys. Res. Commun. 452(3), 2014
PMID: 25218471
ADAM17 at the interface between inflammation and autoimmunity.
Lisi S, D'Amore M, Sisto M., Immunol. Lett. 162(1 Pt A), 2014
PMID: 25171914

64 References

Data provided by Europe PubMed Central.

Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing.
Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawarna K., Nature 370(6486), 1994
PMID: 8028669
The inflammasomes.
Schroder K, Tschopp J., Cell 140(6), 2010
PMID: 20303873
Role of Plk2 (Snk) in mouse development and cell proliferation.
Ma S, Charron J, Erikson RL., Mol. Cell. Biol. 23(19), 2003
PMID: 12972611
TPL2-mediated activation of ERK1 and ERK2 regulates the processing of pre-TNF alpha in LPS-stimulated macrophages.
Rousseau S, Papoutsopoulou M, Symons A, Cook D, Lucocq JM, Prescott AR, O'Garra A, Ley SC, Cohen P., J. Cell. Sci. 121(Pt 2), 2008
PMID: 18187448
Reactive oxygen species and p38 mitogen-activated protein kinase mediate tumor necrosis factor α-converting enzyme (TACE/ADAM-17) activation in primary human monocytes.
Scott AJ, O'Dea KP, O'Callaghan D, Williams L, Dokpesi JO, Tatton L, Handy JM, Hogg PJ, Takata M., J. Biol. Chem. 286(41), 2011
PMID: 21865167
Phosphorylation of synucleins by members of the Polo-like kinase family.
Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, Kahle PJ, Hirling H, Lashuel HA., J. Biol. Chem. 285(4), 2010
PMID: 19889641
Investigation on PLK2 and PLK3 substrate recognition.
Salvi M, Trashi E, Cozza G, Franchin C, Arrigoni G, Pinna LA., Biochim. Biophys. Acta 1824(12), 2012
PMID: 22828320
Polo-box domains confer target specificity to the Polo-like kinase family.
van de Weerdt BC, Littler DR, Klompmaker R, Huseinovic A, Fish A, Perrakis A, Medema RH., Biochim. Biophys. Acta 1783(6), 2008
PMID: 18359294
Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk.
Lee KS, Grenfell TZ, Yarm FR, Erikson RL., Proc. Natl. Acad. Sci. U.S.A. 95(16), 1998
PMID: 9689075
iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding.
Maretzky T, McIlwain DR, Issuree PD, Li X, Malapeira J, Amin S, Lang PA, Mak TW, Blobel CP., Proc. Natl. Acad. Sci. U.S.A. 110(28), 2013
PMID: 23801765
Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.
Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, Rouyrre N, Trommeshauser D, Hoesl CE, Munzert G., J. Clin. Oncol. 26(34), 2008
PMID: 18955456
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, Gurtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ., Curr. Biol. 17(4), 2007
PMID: 17291758

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 24338472
PubMed | Europe PMC

Search this title in

Google Scholar